Based in Arlington, Va., Champions Biotechnology is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The company s preclinical platform is an approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts in a manner that preserves the biological characteristics of the original human tumor. It believes that these Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of therapeutic candidates through preclinical trials. Champions Biotechnology also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care.